Evidence map›Paper›PMID 20060024›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2010

Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery.

J R Eisenbrey, O Mualem Burstein, R Kambhampati, F Forsberg, J-B Liu, M A Wheatley

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 118 citations in OpenAlex.

  1. Article
  2. Overview of Therapeutic Ultrasound Applications and Safety Considerations: 2024 Update.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Ultrasound-responsive polymer-based drug delivery systems.Drug delivery and translational research · 2021
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Breast Cancer Brain Metastasis Response to Radiation After Microbubble Oxygen Delivery in a Murine Model.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

J R EisenbreySchool of Biomedical Engineering, Science and Health Systems, Drexel University, 3141 Chestnut Street, Philadelphia, PA 19104, USA. jeisenbrey@gmail.com
O Mualem Burstein
R Kambhampati
F Forsberg
J-B Liu
M A Wheatley
Drexel University · USThomas Jefferson University · US

Funding

DEVELOPMENT OF A NEW CLASS OF ULTRASOUND CONTRAST AGENTSR01HL052901 · NHLBI · DREXEL UNIVERSITY · PI WHEATLEY, MARGARET A. · 1994 to 2009
$1.9M
NHLBI NIH HHS R01 HL052901PHS HHS 52901
6 · The paper itself

Abstract

An echogenic, intravenous drug delivery platform is proposed in which an encapsulated chemotherapeutic can travel to a desired location and drug delivery can be triggered using external, focused ultrasound at the area of interest. Three methods of loading poly(lactic acid) (PLA) shelled ultrasound contrast agents (UCA) with doxorubicin are presented. Effects on encapsulation efficiency, in vitro enhancement, stability, particle size, morphology and release during UCA rupture are compared by loading method and drug concentration. An agent containing doxorubicin within the shell was selected as an ideal candidate for future hepatocellular carcinoma studies. The agent achieved a maximal drug load of 6.2 mg Dox/g PLA with an encapsulation efficiency of 20.5%, showed a smooth surface morphology and tight size distribution (poly dispersity index=0.309) with a peak size of 1865 nm. Acoustically, the agent provided 19 dB of enhancement in vitro at a dosage of 10 microg/ml, with a half life of over 15 min. In vivo, the agent provided ultrasound enhancement of 13.4+/-1.6 dB within the ascending aorta of New Zealand rabbits at a dose of 0.15 ml/kg. While the drug-incorporated agent is thought to be well suited for future drug delivery experiments, this study has shown that agent properties can be tailored for specific applications based on choice of drug loading method.

Indexed as

Drug CarriersUltrasonicsUltrasonography, Doppler, PulsedAnimalsAntineoplastic AgentsAortaChemistry, PharmaceuticalContrast MediaDoxorubicinDrug CompoundingHalf-LifeInjections, IntravenousKidneyKineticsLactic AcidMicroscopy, ConfocalAntineoplastic AgentsContrast MediaDoxorubicinDrug CarriersLactic AcidPolyesterspoly(lactide)Polymers

Identifiers

PMID20060024
PMCPMC2878717
OpenAlexW2010693340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.